PIRPath: A region-guided weakly supervised pathomics framework for neoadjuvant immunotherapy response prediction across multiple cancer types
Year: 2026
Type: article
Abstract: Background Neoadjuvant immunotherapy is now standard for multiple solid tumors; however, substantial heterogeneity in treatment response remains. Current biomarkers such as programmed death-ligand 1 (PD-L1) capture only limited molecular dimensions of tumor biology. We aimed to predict pathological response from pretreatment hematoxylin and eosin (H&E) whole-slide images (WSIs), benchmark it against PD-L1, and test cross-cancer transferability. Methods Across 320 patients, 377 pretreatment H&E WSIs were processed, yielding 20,247,535 tissue patches. We developed PIRPath (Pathomics for Immunotherapy Response Prediction), a region-guided weakly supervised framework, internally validated in a breast cancer cohort using five-fold cross-validation and further evaluated in two independent external cohorts. Exploratory cross-cancer transfer was assessed in lung cancer and esophageal squamous cell carcinoma cohorts. Results In breast cancer, PIRPath-BC achieved an AUC of 0.9318 (95% CI, 0.8836–0.9713) in internal validation and external AUCs of 0.7991 (95% CI, 0.6000–0.9509) and 0.7292 (95% CI, 0.5333–0.8947). High-score patients showed significantly higher pathological complete response (pCR) rates than low-score patients in both cohorts (78.6%vs 31.2%, P = 0.010; 70.6% vs 35.3%, P = 0.039). In cross-cancer transfer, PIRPath reached 0.7107 for major pathological response (MPR) and 0.7037 for pCR, versus 0.6125 and 0.4590 for PD-L1. Incremental analyses demonstrated additional predictive value beyond PD-L1. Exploratory transcriptomic analyses linked predictions to reduced stromal features and immune activation-related states. Conclusions H&E WSIs contain response-associated histological information not fully captured by conventional biomarkers. PIRPath provides a computational pathology framework for extracting this and complementing existing biomarkers in neoadjuvant immunotherapy stratification, although the modest external cohorts require prospective validation.
Source: Translational Oncology
Language: English
Topic: AI in cancer detection
Subfield: Artificial Intelligence
Field: Computer Science
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $3,390
OpenAlex ID: W7204240075
